Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
106.06
Dollar change
+2.12
Percentage change
2.04
%
Index- P/E23.07 EPS (ttm)4.60 Insider Own3.20% Shs Outstand62.26M Perf Week-2.69%
Market Cap6.69B Forward P/E5.11 EPS next Y20.75 Insider Trans0.12% Shs Float61.02M Perf Month-1.28%
Income330.79M PEG5.37 EPS next Q4.74 Inst Own95.96% Short Float5.37% Perf Quarter-20.12%
Sales3.84B P/S1.74 EPS this Y1.39% Inst Trans-0.76% Short Ratio4.77 Perf Half Y-12.87%
Book/sh58.65 P/B1.81 EPS next Y11.88% ROA2.96% Short Interest3.28M Perf Year-17.85%
Cash/sh28.84 P/C3.68 EPS next 5Y4.30% ROE9.41% 52W Range103.01 - 146.70 Perf YTD-13.77%
Dividend Est.- P/FCF6.61 EPS past 5Y-3.53% ROI3.73% 52W High-27.70% Beta0.62
Dividend TTM- Quick Ratio1.78 Sales past 5Y15.52% Gross Margin73.55% 52W Low2.96% ATR (14)2.83
Dividend Ex-Date- Current Ratio2.15 EPS Y/Y TTM310.66% Oper. Margin15.83% RSI (14)40.22 Volatility2.24% 2.90%
Employees2800 Debt/Eq1.57 Sales Y/Y TTM2.81% Profit Margin8.61% Recom1.55 Target Price180.78
Option/ShortYes / Yes LT Debt/Eq1.40 EPS Q/Q-124.85% Payout0.00% Rel Volume0.98 Prev Close103.94
Sales Surprise-5.45% EPS Surprise-35.87% Sales Q/Q1.03% EarningsMay 01 AMC Avg Volume686.28K Price106.06
SMA20-3.36% SMA50-6.40% SMA200-14.19% Trades Volume675,761 Change2.04%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Initiated Robert W. Baird Outperform $160
Nov-27-23Downgrade UBS Buy → Neutral $170 → $135
Sep-29-23Initiated Raymond James Mkt Perform
Jun-12-23Resumed Wells Fargo Equal Weight $184 → $140
Dec-09-22Upgrade Goldman Neutral → Buy $192 → $190
Jun-14-22Initiated UBS Buy $194
Apr-06-22Downgrade Goldman Buy → Neutral $202 → $196
Nov-19-21Resumed Goldman Buy $198
Oct-07-21Resumed Jefferies Buy $172
Oct-05-21Initiated Citigroup Buy $200
May-23-24 06:00AM
May-22-24 07:01PM
04:00PM
May-17-24 02:32PM
May-09-24 09:19AM
04:30PM Loading…
May-08-24 04:30PM
01:22PM
May-07-24 05:37PM
10:57AM
May-06-24 09:29AM
May-03-24 12:41PM
11:49AM
May-02-24 11:26AM
03:53AM
May-01-24 08:56PM
07:00PM Loading…
07:00PM
04:24PM
04:10PM
04:05PM
Apr-30-24 09:50AM
Apr-24-24 04:05PM
10:01AM
05:21AM
Apr-23-24 11:15AM
Apr-17-24 04:15PM
Apr-10-24 07:45AM
Apr-04-24 09:15AM
Apr-02-24 07:30AM
Mar-29-24 11:30AM
Mar-28-24 10:15AM
10:15AM Loading…
Mar-20-24 10:15AM
Mar-18-24 03:28PM
Mar-17-24 08:50AM
Mar-14-24 12:00PM
10:00AM
Mar-13-24 02:25PM
Mar-12-24 05:34PM
04:15PM
Mar-09-24 11:15AM
Mar-07-24 01:51PM
01:10PM
10:08AM
Feb-29-24 10:45AM
10:35AM
Feb-28-24 06:30PM
05:20PM
04:33PM
04:29PM
04:05PM
Feb-27-24 10:15PM
07:45AM
Feb-24-24 05:06AM
Feb-23-24 09:15AM
Feb-21-24 08:50AM
07:45AM
Feb-20-24 05:00PM
04:15PM
Feb-14-24 04:15PM
Feb-13-24 10:15AM
Feb-09-24 09:15AM
Feb-07-24 07:35AM
02:00AM
Feb-03-24 05:06AM
Jan-31-24 03:33PM
12:03PM
Jan-22-24 05:16AM
Jan-18-24 05:37AM
Jan-13-24 05:06AM
Dec-28-23 10:06PM
Dec-22-23 12:07PM
11:16AM
Dec-21-23 04:17PM
04:09PM
04:05PM
Dec-20-23 04:15PM
05:21AM
Dec-08-23 01:20PM
11:30AM
09:15AM
Dec-01-23 09:02AM
Nov-30-23 07:45AM
Nov-29-23 11:15AM
Nov-28-23 08:48AM
Nov-27-23 09:49AM
Nov-15-23 05:21AM
Nov-14-23 12:50PM
02:00AM
Nov-09-23 05:07PM
Nov-08-23 07:00PM
05:52PM
04:42PM
04:05PM
Nov-07-23 12:33PM
07:45AM
Nov-01-23 04:15PM
10:01AM
Oct-31-23 05:42PM
Oct-30-23 04:05PM
Oct-26-23 11:40AM
Oct-25-23 04:15PM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patil Neena MEVP & Chief Legal OfficerMay 03 '24Sale109.655,000548,25036,629May 07 05:31 PM
Carr PatriciaSVP, Chief Accounting OfficerMar 07 '24Sale116.981,768206,8216,596Mar 08 06:07 PM
Carr PatriciaSVP, Chief Accounting OfficerMar 06 '24Sale119.641,936231,6288,364Mar 08 06:07 PM
Johnson Philip LEVP & Chief Financial OfficerMar 01 '24Buy119.6512,0001,435,80027,932Mar 05 07:28 PM
Cook Jennifer E.DirectorDec 04 '23Sale119.2741749,7366,888Dec 06 04:31 PM
Smith Mark DouglasDirectorDec 04 '23Sale119.2741749,7366,888Dec 06 04:39 PM
Patil Neena MEVP & Chief Legal OfficerSep 01 '23Sale144.251,500216,37529,186Sep 06 05:09 PM
Carr PatriciaSVP, Chief Accounting OfficerAug 29 '23Sale143.4714220,3735,986Aug 31 06:44 PM
Patil Neena MEVP & Chief Legal OfficerAug 15 '23Sale139.59750104,69530,686Aug 17 05:21 PM
McSharry Heather AnnDirectorAug 14 '23Sale138.161,344185,68516,778Aug 15 05:52 PM
O'Keefe Kenneth WDirectorAug 14 '23Sale138.161,241171,45524,723Aug 15 07:49 PM
Sohn Catherine A.DirectorAug 14 '23Sale138.161,241171,45514,868Aug 15 06:02 PM
ENRIGHT PATRICK GDirectorAug 14 '23Sale138.161,241171,45520,946Aug 15 05:45 PM
Winningham Rick EDirectorAug 14 '23Sale138.161,241171,45510,444Aug 15 06:08 PM
Gray PeterDirectorAug 14 '23Sale138.161,241171,45516,068Aug 15 05:47 PM
RIEDEL NORBERT GDirectorAug 14 '23Sale138.161,241171,45413,705Aug 15 05:58 PM
Cook Jennifer E.DirectorAug 14 '23Sale138.161,241171,4547,305Aug 15 05:44 PM
ORiordan AnneDirectorAug 14 '23Sale138.161,241171,45412,551Aug 15 07:51 PM
Smith Mark DouglasDirectorAug 14 '23Sale138.161,241171,4547,305Aug 15 06:00 PM
Carr PatriciaSVP, Chief Accounting OfficerAug 14 '23Sale138.1615821,8296,128Aug 15 05:43 PM
Mulligan SeamusDirectorJun 08 '23Option Exercise81.764,500367,9201,169,300Jun 12 04:47 PM
Carr PatriciaSVP, Chief Accounting OfficerJun 07 '23Sale127.9212616,1176,286Jun 09 04:55 PM
Patil Neena MEVP & Chief Legal OfficerJun 01 '23Sale127.981,600204,76332,826Jun 05 08:24 PM